Olympia Pharmaceuticals

Olympia runs both an FDA-registered 503B outsourcing facility and an affiliated 503A pharmacy (“Olympia Pharmacy”) out of Orlando — so, like Empower and Belmar, it can serve both office-use batches and patient-specific prescriptions.

Facility & accreditation

Olympia appears on the FDA Registered Outsourcing Facilities (503B) list as “Olympia Pharmaceuticals, Orlando, FL” (initial registration March 10, 2014; most recent November 20, 2025) ^[1], and describes itself as an FDA-registered 503B outsourcing facility plus a 503A compounding pharmacy ^[2]. Its site shows a LegitScript certification and an NABP badge ^[2]. LegitScript’s own lookup lists olympiapharmacy.com as Certified, website type Pharmacy ^[5]. We did not confirm the NABP badge with NABP, and a direct search of ACHC’s PCAB directory returned no PCAB accreditation for the Orlando pharmacy ^[4] (the “Olympia” entries there are unrelated home-health organizations). The company says it is licensed in 49 states (all except California) ^[2].

What they compound

Relevant lines: a dedicated peptides category, weight management, hormones (BHRT/TRT), IV nutrition, sexual health (including TriMix), dermatology, and other injectables ^[2]. Named compounded GLP-1 (semaglutide/tirzepatide) listings were not confirmed from the pages we reviewed.

Regulatory record

As of our July 2026 read of the FDA 503B list, Olympia’s most recent inspection had run July 28–August 8, 2025 and resulted in a Form 483; recall status is “No,” and the action based on the last inspection is “Open,” with an FDA flag indicating a prior compounding-related action in its history ^[1]. The Form 483 (issued August 12, 2025) lists three observations centered on aseptic-process validation, written production/process-control procedures, and cleaning/disinfection practices in aseptic areas ^[3]. A Form 483 records inspection observations, not a final finding of violation; no warning letter or recall is listed in the current table. Dated to our review; status can change.

FDA inspected the Orlando outsourcing facility again from August 20 to September 3, 2026 and issued a second Form 483 on September 3, 2026, with eight observations ^[6]. They cover environmental monitoring in the aseptic processing areas, procedures to prevent microbial contamination of sterile products, production and process-control procedures, a stability program without reliable test methods (it names the beyond-use date the firm assigns to its sermorelin acetate 0.9 mg/mL injection), separation of aseptic operations, component testing, and second-person checks when components are added to a batch. As with the 2025 document, these are an investigator’s observations, not a final FDA finding. FDA’s compounding-actions list shows no warning letter, and its Enforcement Report no recall, for Olympia as of October 28, 2026.

The read

A long-established dual-status compounder (503B since 2014) with a broad peptide/HRT/weight/IV catalog and near-national licensure. Form 483s from two consecutive inspections (2025 and 2026) and the prior-action flag are the items to watch — normal to track for a facility of this age and scale, but worth noting alongside the newer entrants.

References

1. FDA — Registered Outsourcing Facilities (503B) list. (accessed 2026-07-01)
2. Olympia Pharmaceuticals / Olympia Pharmacy — official site. (accessed 2026-07-01)
3. FDA — Form 483, Olympia Pharmaceuticals (issued 2025-08-12). (accessed 2026-07-01)
4. ACHC / PCAB accredited-organization directory (searched “Olympia”). (accessed 2026-10-27)
5. LegitScript — website certification status, olympiapharmacy.com: Certified. (accessed 2026-10-27)
6. FDA — Form 483, OPS International Inc dba Olympia Pharmaceuticals, Orlando, FL (issued 2026-09-03). (accessed 2026-10-28)